HealthTree Logo
search more_vert
person Sign In / Create Account
HealthTree's ASH 2023 Myeloma Summary
Posted: Jan 30, 2024
HealthTree's ASH 2023 Myeloma Summary image

Over the past two months, we've been covering important information presented at one of the biggest myeloma academic conferences of the year. We are now concluding our coverage of this important event. 

The 65th annual American Society of Hematology (ASH) Conference brought us a lot of important data regarding how patient populations are responding to treatment, the influence of novel treatments like CAR-T and bispecific antibody therapy, how patients and caregivers can improve their quality of life, and more. 

I'm grateful to my team: Beth Travis, Diane Kennedy, Todd Kennedy, Bonnie Falbo, Valarie Traynham, and Rozalynn Hite, who worked many hours to make this research available and understandable to you. Enjoy! 

To read what we covered from this past year's ASH conference, read below:

General ASH 2023 Articles

Welcome to ASH 2023!

Bispecific Antibody Therapy Articles 

An Indirect Comparison of Elranatamab and Teclistamab

How Tocilizumab Prevents CRS with Teclistamab Administration

How Do We Apply T-Cell Redirection for Myeloma? Part 1: Bispecific Antibody Therapies

Bispecific Therapy for High-Risk Smoldering Myeloma

CAR-T Therapy Articles 

Raising the BCMA Standard in Multiple Myeloma

The Risk of Secondary Cancers with CAR-T Therapy 

The Next Frontier in CAR T-Cell Therapy- GPRC5D: Auto & Allo in the Spotlight

The Effect of Stem Cell Infusion on ICAHT after CAR-T Cell Therapy

Understanding Myeloma Progression, Relapse, and Survival Probability Articles 

T-Cell Exhaustion Predicts Early Relapse after SCT in Myeloma

Can You Slow Your Myeloma Progression by Eating a Plant-Based Diet?

Dynamic Frailty Status Could Provide Better Prediction of Survival Probability

Minimal Residual Disease in Myeloma Articles 

What Do Myeloma Patients Think About MRD Testing?

Financial and Quality of Life Articles 

How Financial Toxicity is Affecting Myeloma Patients and Their Families

Downshifting to Upshift: Changing the Way We Think

Caregiver Distress – How Are You, REALLY?

How Your Insurance Type May Affect Your Blood Cancer Outcome

Finding Renewed Purpose with Myeloma

How Willing Are Black Myeloma Patients to Participate in Clinical Trials?

Groundbreaking Research on Myeloma Treatments

Down with Dex! New Research Reveals Dexamethasone Dosing Can Be Reduced

PERSEUS and IsKia Trials Support a New Standard of Care for Transplant Eligible Newly Diagnosed Myeloma Patients

Using Venetoclax with 11;14 Myeloma Patients

How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024?

Real-World Velcade Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma

High-Risk Smoldering and Active Myeloma Response Articles 

How Extramedullary and High-Risk Myeloma Patients Are Responding to Immunotherapy

High-Risk Smoldering Myeloma: To Treat or Not to Treat?

ASH 2023 Resources

Would you like to watch ASH 2023 myeloma research interviews from the investigators themselves? Click "ASH 2023" here: HealthTree University Conference Coverage

To read all of the ASH 2023 articles, click here: HealthTree 2023 ASH Articles 

The author Audrey Burton-Bethke

about the author
Audrey Burton-Bethke

Audrey is a content writer and editor for the HealthTree Foundation. She originally joined the HealthTree Foundation in 2020. Audrey loves spending time with her supportive husband, energetic four-year-old, and new baby. 

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube